1. [Efficacy of Activated Autologous Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia].
- Author
-
Ren RR, Ma LM, Wang T, Xie YX, Zhu QJ, Gao ZL, Tian WW, Gong R, and Niu YY
- Abstract
Objective: To compare the efficacy of activated autologous bone marrow and peripheral blood hematopoietic stem cell transplantation (Auto-HSCT) and matched sibling donor allogeneic hematopoietic stem cell transplantation (MSD-HSCT) for the first complete remission of adult acute myeloid leukemia (AML-CR1)., Methods: For 86 adult patients with first complete remission of AML who underwent auto-HSCT (41 cases) and MSD-HSCT (45 cases) in our hospital from June 2012 to June 2020, the patients were treated with modified MAC [Malflane 160 mg/(m
2 ·d), -3 days, Ara-C 2 g/(m2 ·2), -3 days 21∶00, -2 days 9∶00, CTX 60 mg/(kg·d),-3 d, -2 d], the stem cells were activated by IL-2 (1 000 U/ mL), IFN-α (100 U/ mL) and IFN-γ (100 U/ml). The overall survival (OS), leukemia free survival (LFS), cumulative incidence of recurrence (CIR) and non-recurrence mortality (NRM) of patients with different types of transplantation were compared., Results: The 3-year OS rates of Auto-HSCT group and MSD-HSCT group were 75% and 69.5%, and the 3-year LFS rates were 70.6% and 82.4%, respectively. There was no statisticaly significant difference in the 3-year OS rates of low risk, medium risk and high risk patients in the Auto-HSCT and MSD-HSCT group (90.2% vs 87.5%, 68.4% vs 68.8%, 28.6% vs 53.3%), the LFS rates of low risk, medium risk and high risk patients in the auto-HSCT and MSD-HSCT group were 90.2% and 87.5%( P =0.838), 71.8% and 91.7%( P =0.184), 0 and 67.5%( P =0.027), respectively. The NRM of Auto-HSCT and MSD-HSCT group were 4.9% and 20% ( P =0.036), and CIR were 24.4% and 13.3% ( P =0.188). Univariate analysis showed that the survival time of patients was significantly correlated with the number of CR courses and disease risk stratification ( P =0.005, P =0.000). Cox multivariate analysis showed that disease risk stratification was an independent risk factor affecting OS ( P =0.001)., Conclusion: For adult patients with primary AML-CR1, Auto-HSCT is safe and effective. In the absence of sibling donor, Auto-HSCT can be regarded as an effective post-remission treatment for patients with intermediate risk AML-CR1.- Published
- 2023
- Full Text
- View/download PDF